Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nortriptyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.97 |
| ▸ | HRH1 | P35367 | 6/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.97 |
| ▸ | HTR2B | P41595 | 5/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.97 |
| ▸ | DRD2 | P14416 | 4/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nortriptyline SCHEMBL29751879 | 1.00 | CYP3A4 (1.00) | CYP3A4SLC6A2LMNAPMP22MEN1 | |
| Nortriptyline SCHEMBL29362430 | 0.98 | SLC6A2 (1.00) | CYP3A4SLC6A2LMNAPMP22MEN1 | |
| Nortriptyline SCHEMBL1286980 | 0.98 | SLC6A2 (1.00) | CYP3A4SLC6A2LMNAPMP22MEN1 | |
| Nortriptyline SCHEMBL34527 | 0.98 | SLC6A2 (1.00) | CYP3A4SLC6A2LMNAPMP22MEN1 | |
| Nortriptyline SCHEMBL7158809 | 0.97 | SLC6A2 (0.97) | CYP3A4SLC6A2LMNAPMP22MEN1 | |
| Nortriptyline SCHEMBL2244623 | 0.95 | SLC6A2 (0.94) | CYP3A4SLC6A2LMNAPMP22MEN1 | |
| Nortriptyline SCHEMBL7092935 | 0.95 | LMNA (0.94) | CYP3A4SLC6A2LMNAPMP22MEN1 | |
| Nortriptyline SCHEMBL29564547 | 0.89 | LMNA (0.80) | CYP3A4SLC6A2LMNAPMP22MEN1 | |
| Amitriptyline SCHEMBL3897883 | 0.88 | SLC6A2 (0.81) | CYP3A4SLC6A2LMNAPMP22MEN1 | |
| Hydrochloric Acid SCHEMBL11526607 | 0.88 | LMNA (0.77) | CYP3A4SLC6A2LMNAPMP22MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5263 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130868-A1 | METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS VIA ADMINISTRATION OF ORGANIC TRICYCLIC COMPOUNDS | SYNGAP RES FUND (US) | 2026-05-14 | — | — | US | claimed |
| EP-4725506-A2 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-3986401-B1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | STEALTH BIOTHERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| US-12419845-B1 | Methods for treating neurodevelopmental disorders via administration of organic tricyclic compounds | SynGAP Research Fund (US) | 2025-09-23 | — | — | US | claimed |
| US-20250281427-A1 | METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS VIA ADMINISTRATION OF ORGANIC TRICYCLIC COMPOUNDS | SynGAP Research Fund | 2025-09-11 | — | — | US | claimed |
| US-20250275924-A1 | Anticholinergic Agents and Muscarinic Agonists for the Treatment of Demodex Related Conditions | ATTILLAPS HOLDINGS INC. | 2025-09-04 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| EP-0980247-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | Algos Pharmaceutical Corporation (US) | 2000-02-23 | — | — | EP | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1998050044-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| US-4977145-A | ADMINISTERING ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1990-12-11 | — | — | US | claimed |
| US-4593031-A | Administering and amine substituted dibenzocycloheptane compound | SANDOZ, INC. (US) | 1986-06-03 | — | — | US | claimed |